Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 9, 2026, 11:15 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 128 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Atomoxetine Hydrochloride, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
502 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
20
States / cities
Irvine, California • Gainesville, Florida • Tampa, Florida + 17 more
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
MPH (Concerta), MPH (Ritalin), Atomoxetine (ATO), Guanfacine (GFC)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
Not listed
Enrollment
17,418 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Titusville, New Jersey
Conditions
Binge-eating Disorder
Interventions
atomoxetine
Drug
Lead sponsor
Lindner Center of HOPE
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Cincinnati, Ohio
Conditions
Substance Use Disorders, Attention Deficit Hyperactivity Disorder
Interventions
Atomoxetine
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
13 Years to 18 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Conditions
Autism
Interventions
Atomoxetine, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
5 Years to 15 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
2
States / cities
Indianapolis, Indiana • Lexington, Massachusetts
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Guanfacine hydrochloride (TAK-503), Atomoxetine hydrochloride, Placebo
Drug · Other
Lead sponsor
Shire
Industry
Eligibility
6 Years to 17 Years
Enrollment
396 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
20
States / cities
Dothan, Alabama • Anaheim, California • Imperial, California + 17 more
Recruiting Phase 1Phase 2 Interventional

Atomoxetine and DAW2022 on OSA Severity

NCT05350215
Conditions
Obstructive Sleep Apnea
Interventions
Placebo oral capsule, Atomoxetine Oral Capsule [Strattera]
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
21 Years to 70 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Attention Deficit Hyperactivity Disorder, Comorbid Social Anxiety Disorder
Interventions
Atomoxetine hydrochloride, placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
440 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
20
States / cities
Wildomar, California • Bradenton, Florida • Gainesville, Florida + 17 more
Completed Phase 3 Interventional Results available

Long-Term, Open Label Atomoxetine Study

NCT00190684
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
atomoxetine
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
6 Years to 18 Years
Enrollment
1,553 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2009
U.S. locations
70
States / cities
Birmingham, Alabama • Phoenix, Arizona • El Centro, California + 67 more
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Atomoxetine
Drug
Lead sponsor
Monarch Medical Research
Other
Eligibility
6 Years to 18 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Norfolk, Virginia
Conditions
Marijuana Abuse, Attention Deficit Disorder With Hyperactivity
Interventions
Atomoxetine, Motivational enhancement therapy, Placebo
Drug · Procedure
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 65 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Charleston, South Carolina
Conditions
Neurogenic Orthostatic Hypotension
Interventions
Atomoxetine, Placebo
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
40 Years to 80 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
2
States / cities
New York, New York • Nashville, Tennessee
Conditions
ADHD NOS
Interventions
atomoxetine (Strattera)
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Cambridge, Massachusetts
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Atomoxetine Hydrochloride
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
6 Years to 16 Years
Enrollment
377 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Scottsdale, Arizona
Conditions
Methamphetamine Abuse, Methamphetamine Dependence
Interventions
Atomoxetine, then Placebo, Placebo, then Atomoxetine
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 50 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Los Angeles, California
Terminated Phase 1 Interventional Results available

Orthostatic Intolerance After Bariatric Surgery

NCT03808740
Conditions
Orthostatic Intolerance
Interventions
Atomoxetine, Placebo
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 60 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Nashville, Tennessee
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Evaluation of Atomoxetine for Cocaine Dependence: A Pilot Trial

NCT00617201
Conditions
Substance Abuse
Interventions
atomoxetine, placebo
Drug
Lead sponsor
Sharon Walsh
Other
Eligibility
18 Years to 60 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2011
U.S. locations
1
States / cities
Lexington, Kentucky
Conditions
Fetal Alcohol Syndrome, Attention Deficit Disorder With Hyperactivity (ADHD), Attention Deficit Disorder (ADD)
Interventions
Strattera, Placebo
Drug
Lead sponsor
University of Oklahoma
Other
Eligibility
4 Years to 11 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2015
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Conditions
Cocaine Dependence, Opiate Dependence
Interventions
Atomoxetine, low dose, Atomoxetine, high dose, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
West Haven, Connecticut
Completed Early Phase 1 Interventional Accepts healthy volunteers

Mechanisms of Hypoglycemia Associated Autonomic Dysfunction, Q4-Atomoxetine

NCT00780650
Conditions
Type 1 Diabetes
Interventions
Atomoxetine, Placebo
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 50 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Menopause, Cognitive Disturbances
Interventions
atomoxetine, placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
45 Years to 60 Years · Female only
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2008
U.S. locations
1
States / cities
New Haven, Connecticut
Conditions
Depressive Disorder, Parkinson Disease
Interventions
Atomoxetine, Placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
30 Years to 79 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
2
States / cities
Philadelphia, Pennsylvania
Conditions
Adult Attention Deficit Hyperactivity Disorder
Interventions
OPC-64005, Atomoxetine, Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
239 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
26
States / cities
Beverly Hills, California • Garden Grove, California • San Diego, California + 20 more
Completed Phase 1Phase 2 Interventional Results available

Clinical Efficacy of Atomoxetine for Methamphetamine Dependence

NCT01557569
Conditions
Methamphetamine Dependence
Interventions
Atomoxetine, placebo
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Little Rock, Arkansas